Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy
The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity...
Saved in:
| Published in: | PLoS neglected tropical diseases Vol. 18; no. 1; p. e0011901 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Public Library of Science
01-01-2024
Public Library of Science (PLoS) |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO/MDT.
This is a case-control study that involved the review of medical records of adult (≥18 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer-Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC).
A total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03-6.59), multibacillary classification (OR = 2.5; 95% CI: 1.39-4.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14-3.47) were considered factors to predict ADEs that caused standard WHO/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs.
We propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients. |
|---|---|
| AbstractList | BACKGROUNDThe occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO/MDT.METHODOLOGYThis is a case-control study that involved the review of medical records of adult (≥18 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer-Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC).RESULTSA total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03-6.59), multibacillary classification (OR = 2.5; 95% CI: 1.39-4.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14-3.47) were considered factors to predict ADEs that caused standard WHO/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs.CONCLUSIONWe propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients. Background The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO/MDT. Methodology This is a case-control study that involved the review of medical records of adult ([greater than or equal to]18 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer-Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC). Results A total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03-6.59), multibacillary classification (OR = 2.5; 95% CI: 1.39-4.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14-3.47) were considered factors to predict ADEs that caused standard WHO/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs. Conclusion We propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients. Background The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO/MDT. Methodology This is a case-control study that involved the review of medical records of adult (≥18 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer–Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC). Results A total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03–6.59), multibacillary classification (OR = 2.5; 95% CI: 1.39–4.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14–3.47) were considered factors to predict ADEs that caused standard WHO/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs. Conclusion We propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients. The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO/MDT. This is a case-control study that involved the review of medical records of adult (≥18 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer-Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC). A total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03-6.59), multibacillary classification (OR = 2.5; 95% CI: 1.39-4.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14-3.47) were considered factors to predict ADEs that caused standard WHO/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs. We propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients. Adverse events (AE) produced by the drugs used to treat leprosy can hinder the successful completion of the therapeutic regimen. Well-known AE produced by dapsone (DDS) are related to liver problems, allergic reactions, or to the destruction of red and/or white blood cells, causing anemia. Helping the physician to recognize a patient that may develop these adverse reactions can be useful. Thus, we developed a model to predict AE in patients with leprosy receiving standard World Health Organization-recommended multidrug therapy (WHO/MDT). Our question was whether we could use sociodemographic and clinical variables to generate a predictive model for DDS-ADEs. The model developed in this study could be a useful tool to assist physicians in predicting DDS-ADEs when treating patients with standard WHO/MDT for leprosy, and thus, establish a safer therapeutic plan for patients with a greater ADE risk. The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful completion of the standardized therapeutic regimen for this disease. Well-known DDS-ADEs are hemolytic anemia, methemoglobinemia, hepatotoxicity, agranulocytosis, and hypersensitivity reactions. Identifying risk factors for ADEs before starting World Health Organization recommended standard multidrug therapy (WHO/MDT) can guide therapeutic planning for the patient. The objective of this study was to develop a predictive model for DDS-ADEs in patients with leprosy receiving standard WHO/MDT. This is a case-control study that involved the review of medical records of adult ([greater than or equal to]18 years) patients registered at a Leprosy Reference Center in Rio de Janeiro, Brazil. The cohort included individuals that received standard WHO/MDT between January 2000 to December 2021. A prediction nomogram was developed by means of multivariable logistic regression (LR) using variables. The Hosmer-Lemeshow test was used to determine the model fit. Odds ratios (ORs) and their respective 95% confidence intervals (CIs) were estimated. The predictive ability of the LRM was assessed by the area under the receiver operating characteristic curve (AUC). A total of 329 medical records were assessed, comprising 120 cases and 209 controls. Based on the final LRM analysis, female sex (OR = 3.61; 95% CI: 2.03-6.59), multibacillary classification (OR = 2.5; 95% CI: 1.39-4.66), and higher education level (completed primary education) (OR = 1.97; 95% CI: 1.14-3.47) were considered factors to predict ADEs that caused standard WHO/MDT discontinuation. The prediction model developed had an AUC of 0.7208, that is 72% capable of predicting DDS-ADEs. We propose a clinical model that could become a helpful tool for physicians in predicting ADEs in DDS-treated leprosy patients. |
| Audience | Academic |
| Author | Hacker, Mariana de Andrea Vilas-Boas Durães, Sandra Maria Barbosa Sales, Anna Maria de Araujo, Ana Carolina Galvão Dos Santos Pinheiro, Roberta Olmo Illarramendi, Ximena Moraes, Milton Ozório Nobre, Maurício Lisboa da Silva, Gilberto Marcelo Sperandio |
| AuthorAffiliation | Federal University of Ceará, Fortaleza, Brazil, BRAZIL 2 Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil 4 Giselda Trigueiro Hospital, Rio Grande do Norte Federal State Public Health department (SESAP-RN), Natal, RN, Brazil 1 Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil 3 Dermatology Department, Fluminense Federal University (UFF), Niterói, RJ, Brazil |
| AuthorAffiliation_xml | – name: 4 Giselda Trigueiro Hospital, Rio Grande do Norte Federal State Public Health department (SESAP-RN), Natal, RN, Brazil – name: Federal University of Ceará, Fortaleza, Brazil, BRAZIL – name: 2 Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil – name: 3 Dermatology Department, Fluminense Federal University (UFF), Niterói, RJ, Brazil – name: 1 Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil |
| Author_xml | – sequence: 1 givenname: Ana Carolina Galvão Dos Santos orcidid: 0000-0002-5287-8697 surname: de Araujo fullname: de Araujo, Ana Carolina Galvão Dos Santos organization: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil – sequence: 2 givenname: Mariana de Andrea Vilas-Boas surname: Hacker fullname: Hacker, Mariana de Andrea Vilas-Boas organization: Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil – sequence: 3 givenname: Roberta Olmo surname: Pinheiro fullname: Pinheiro, Roberta Olmo organization: Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil – sequence: 4 givenname: Ximena surname: Illarramendi fullname: Illarramendi, Ximena organization: Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil – sequence: 5 givenname: Sandra Maria Barbosa surname: Durães fullname: Durães, Sandra Maria Barbosa organization: Dermatology Department, Fluminense Federal University (UFF), Niterói, RJ, Brazil – sequence: 6 givenname: Maurício Lisboa surname: Nobre fullname: Nobre, Maurício Lisboa organization: Giselda Trigueiro Hospital, Rio Grande do Norte Federal State Public Health department (SESAP-RN), Natal, RN, Brazil – sequence: 7 givenname: Milton Ozório surname: Moraes fullname: Moraes, Milton Ozório organization: Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil – sequence: 8 givenname: Anna Maria surname: Sales fullname: Sales, Anna Maria organization: Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil – sequence: 9 givenname: Gilberto Marcelo Sperandio surname: da Silva fullname: da Silva, Gilberto Marcelo Sperandio organization: Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38271456$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1r2zAUhs3oWD-2fzA2wWDsJpll2bJ9VUr30UKhNxu7FMfScaIgS54kZ-Qv7FdPadKSjKIL6-N53yMdv-fZiXUWs-wtzeeU1fTzyk3egpmPNqp5nlPa5vRFdkZbVs2KmlUnB_PT7DyEVZ5XbdXQV9kpa4qalhU_y_5-wTUaNw5oI3E9ATJMJuo1eA0RyehRaZnWSAan0JDeeaJgDOkuBNQafUCi_LQgycbGQLQlI7rRIPmj45IYHL0LGzJZhZ6ECFaBV-TXzf2uzoM0LtHDuHmdvezBBHyz_15kP799_XF9M7u7_357fXU3k7yo4oxBzgvKlCpZ13YKu5artuTAoMo57Yqe9wWjvWJcplMAKSntgFHa11ylJbvI3u98R-OC2LcxCJbzljasrPNE3O4I5WAlRq8H8BvhQIuHDecXAnzU0qCgvaTQFwVvq65sm66RdSoEXcU72TQKktflvtrUDahk6pIHc2R6fGL1UizcWtC8KTlvm-Twae_g3e8JQxSDDhKNAYtuCqJoi6Itm4bxhH74D33-eXtqAekF2vYuFZZbU3FVN7Qoa8a21PwZKg2Fg5bp__c67R8JPh4IlggmLoMzU9TOhmOw3IEyZSN47J-6QXOxzfbjrcU222Kf7SR7d9jJJ9FjmNk_I4L7bA |
| CitedBy_id | crossref_primary_10_1007_s40278_024_53742_z |
| Cites_doi | 10.1186/s12885-022-09599-w 10.1016/j.alit.2019.03.006 10.1038/s41467-022-35266-6 10.3390/ijms21175953 10.1056/NEJMoa1213096 10.1371/journal.pntd.0000488 10.2146/ajhp160961 10.47878/hi.1995.v20.36487 10.47276/lr.84.3.209 10.2165/00003088-198916060-00003 10.1590/S0037-86822002000500005 10.1186/s13293-020-00308-5 10.47276/lr.91.3.232 10.2340/00015555-1268 10.47276/lr.78.3.216 10.1345/aph.1Q139 10.47878/hi.2014.v39.35024 10.1007/s00210-022-02297-1 10.1016/j.det.2007.11.007 10.1016/S0733-8635(05)70231-X 10.1016/j.jid.2022.10.009 10.1016/j.bcp.2020.113993 10.1016/j.abd.2020.07.005 10.1097/FPC.0000000000000306 10.1038/clpt.1981.154 10.1371/journal.pntd.0008746 10.1371/journal.pone.0189322 10.3748/wjg.v22.i35.7908 10.1186/s12879-019-4665-0 10.47276/lr.83.3.221 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2024 Public Library of Science 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 de Araujo et al 2024 de Araujo et al 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2024 Public Library of Science – notice: 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 de Araujo et al 2024 de Araujo et al – notice: 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7SS 7T2 7T7 7U9 7X7 7XB 88E 8C1 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO F1W FR3 FYUFA GHDGH H94 H95 H97 K9. L.G M0S M1P M7N P64 PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1371/journal.pntd.0011901 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Entomology Abstracts (Full archive) Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central ASFA: Aquatic Sciences and Fisheries Abstracts Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality ProQuest Health & Medical Complete (Alumni) Aquatic Science & Fisheries Abstracts (ASFA) Professional Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Aquatic Science & Fisheries Abstracts (ASFA) Professional Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Central China Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Health & Safety Science Abstracts Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Entomology Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ASFA: Aquatic Sciences and Fisheries Abstracts Engineering Research Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Education |
| DocumentTitleAlternate | Prediction model for adverse events to dapsone in leprosy treatment |
| EISSN | 1935-2735 |
| Editor | Ramos, Alberto Novaes |
| Editor_xml | – sequence: 1 givenname: Alberto Novaes surname: Ramos fullname: Ramos, Alberto Novaes |
| EndPage | e0011901 |
| ExternalDocumentID | 3069183470 oai_doaj_org_article_1fc1af22695b498b8c71f7ab56bc88da A781247330 10_1371_journal_pntd_0011901 38271456 |
| Genre | Journal Article |
| GeographicLocations | Brazil |
| GeographicLocations_xml | – name: Brazil |
| GrantInformation_xml | – fundername: ; grantid: 312802/2020-0 – fundername: ; grantid: E-26/201.176/2021 (260734) – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7X7 88E 8C1 8FI 8FJ AAFWJ ABDBF ABUWG ACGFO ACIHN ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAP EAS EBD ECGQY ECM EIF EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW IPNFZ ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO PV9 RIG RNS RPM RZL SV3 TR2 TUS UKHRP WOQ AAYXX CITATION AFPKN 7QL 7SS 7T2 7T7 7U9 7XB 8FD 8FK AZQEC C1K DWQXO F1W FR3 H94 H95 H97 K9. L.G M7N P64 PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c625t-3a06213dd43b9bdeb96d946a3a5061b2f6f231fd36cbdeaacc11ba311f76daac3 |
| IEDL.DBID | RPM |
| ISSN | 1935-2735 1935-2727 |
| IngestDate | Wed Nov 27 01:31:07 EST 2024 Tue Oct 22 15:15:56 EDT 2024 Tue Sep 17 21:30:01 EDT 2024 Fri Oct 25 23:55:11 EDT 2024 Thu Oct 10 22:30:58 EDT 2024 Tue Nov 19 21:46:33 EST 2024 Wed Nov 13 00:02:18 EST 2024 Tue Aug 20 22:14:03 EDT 2024 Thu Nov 21 23:43:58 EST 2024 Sat Nov 02 12:27:43 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright: © 2024 de Araujo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c625t-3a06213dd43b9bdeb96d946a3a5061b2f6f231fd36cbdeaacc11ba311f76daac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors have declared that no competing interests exist. |
| ORCID | 0000-0002-5287-8697 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846698/ |
| PMID | 38271456 |
| PQID | 3069183470 |
| PQPubID | 1436337 |
| ParticipantIDs | plos_journals_3069183470 doaj_primary_oai_doaj_org_article_1fc1af22695b498b8c71f7ab56bc88da pubmedcentral_primary_oai_pubmedcentral_nih_gov_10846698 proquest_miscellaneous_2922948836 proquest_journals_3069183470 gale_infotracmisc_A781247330 gale_infotracacademiconefile_A781247330 gale_healthsolutions_A781247330 crossref_primary_10_1371_journal_pntd_0011901 pubmed_primary_38271456 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PLoS neglected tropical diseases |
| PublicationTitleAlternate | PLoS Negl Trop Dis |
| PublicationYear | 2024 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | J Stein (pntd.0011901.ref035) 2016; 22 P Manickam (pntd.0011901.ref001) 2016; 144 J hoon Lee (pntd.0011901.ref007) 2020; 21 RMM Kubota (pntd.0011901.ref023) 2014 RH Gelber (pntd.0011901.ref004) 2012; 83 JA Barclay (pntd.0011901.ref015) 2011; 45 ER Honrado (pntd.0011901.ref018) 2008; 26 PP Raj (pntd.0011901.ref030) 1988; 60 U Paniker (pntd.0011901.ref005) 2001; 19 pntd.0011901.ref019 KM Dupnik (pntd.0011901.ref025) 2013; 84 VD Tortelly (pntd.0011901.ref011) 2021; 96 M Lazo-Porras (pntd.0011901.ref020) 2020; 20 I Zucker (pntd.0011901.ref026) 2020; 11 K. Venkatesan (pntd.0011901.ref029) 1989; 16 LAB Wilson (pntd.0011901.ref027) 2022; 13 C Costa (pntd.0011901.ref028) 2023 E Kindie (pntd.0011901.ref032) 2017; 12 IMB Goulart (pntd.0011901.ref016) 2002; 35 FR Zhang (pntd.0011901.ref008) 2013; 369 pntd.0011901.ref002 R Hilder (pntd.0011901.ref038) 2020; 91 KD Belfield (pntd.0011901.ref037) 2018; 75 CA Naranjo (pntd.0011901.ref022) 1981; 30 M Khalilzadeh (pntd.0011901.ref006) 2022; 395 H Krismawati (pntd.0011901.ref036) 2020; 14 O Yun (pntd.0011901.ref021) 2009; 3 M Lorenz (pntd.0011901.ref009) 2012; 92 H Buttle G A (pntd.0011901.ref003) 1937; 229 L Sun (pntd.0011901.ref013) 2023; 143 T Shiohara (pntd.0011901.ref034) 2019; 68 PD Deps (pntd.0011901.ref017) 2007; 78 J George (pntd.0011901.ref031) 2020; 177 WH Jopling (pntd.0011901.ref024) 1983; 54 JH Richardus (pntd.0011901.ref010) 1989; 60 T Tempark (pntd.0011901.ref012) 2017; 27 R Du (pntd.0011901.ref033) 2022; 22 MEN Gallo (pntd.0011901.ref014) 1995 |
| References_xml | – volume: 60 start-page: 400 issue: 3 year: 1988 ident: pntd.0011901.ref030 article-title: Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy publication-title: Indian J Lepr contributor: fullname: PP Raj – volume: 22 start-page: 491 issue: 1 year: 2022 ident: pntd.0011901.ref033 article-title: The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy publication-title: BMC Cancer doi: 10.1186/s12885-022-09599-w contributor: fullname: R Du – volume: 68 start-page: 301 issue: 3 year: 2019 ident: pntd.0011901.ref034 article-title: Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019 publication-title: Allergol Int doi: 10.1016/j.alit.2019.03.006 contributor: fullname: T Shiohara – volume: 13 start-page: 7502 issue: 1 year: 2022 ident: pntd.0011901.ref027 article-title: Sex differences in allometry for phenotypic traits in mice indicate that females are not scaled males publication-title: Nat Commun doi: 10.1038/s41467-022-35266-6 contributor: fullname: LAB Wilson – volume: 229 start-page: 1331 year: 1937 ident: pntd.0011901.ref003 article-title: The treatment of streptococcal infections in mice with 4:20 diaminodiphenylsulfone contributor: fullname: H Buttle G A – year: 2023 ident: pntd.0011901.ref028 article-title: Factors associated with underreporting of adverse drug reactions by patients: a systematic review publication-title: Int J Clin Pharm contributor: fullname: C Costa – volume: 54 issue: 4 year: 1983 ident: pntd.0011901.ref024 article-title: Side-effects of antileprosy drugs in common use publication-title: Lepr Rev contributor: fullname: WH Jopling – volume: 21 start-page: 5953 issue: 17 year: 2020 ident: pntd.0011901.ref007 article-title: 4,4′-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor publication-title: Int J Mol Sci doi: 10.3390/ijms21175953 contributor: fullname: J hoon Lee – volume: 369 start-page: 1620 issue: 17 year: 2013 ident: pntd.0011901.ref008 article-title: HLA-B*13:01 and the dapsone hypersensitivity syndrome publication-title: N Engl J Med doi: 10.1056/NEJMoa1213096 contributor: fullname: FR Zhang – volume: 3 start-page: e488 issue: 7 year: 2009 ident: pntd.0011901.ref021 article-title: Feasibility, Drug Safety, and Effectiveness of Etiological Treatment Programs for Chagas Disease in Honduras, Guatemala, and Bolivia: 10-Year Experience of Médecins Sans Frontières publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0000488 contributor: fullname: O Yun – volume: 60 issue: 4 year: 1989 ident: pntd.0011901.ref010 article-title: Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy publication-title: Lepr Rev contributor: fullname: JH Richardus – volume: 75 start-page: 97 issue: 3 year: 2018 ident: pntd.0011901.ref037 article-title: Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp160961 contributor: fullname: KD Belfield – start-page: 46 year: 1995 ident: pntd.0011901.ref014 article-title: Intercorrências pelas drogas utilizadas nos esquemas poliquimioterápicos em hanseníase publication-title: Hansen Int doi: 10.47878/hi.1995.v20.36487 contributor: fullname: MEN Gallo – volume: 84 start-page: 209 issue: 3 year: 2013 ident: pntd.0011901.ref025 article-title: Intolerance to leprosy multi-drug therapy: more common in women? publication-title: Lepr Rev doi: 10.47276/lr.84.3.209 contributor: fullname: KM Dupnik – volume: 16 start-page: 365 issue: 6 year: 1989 ident: pntd.0011901.ref029 article-title: Clinical Pharmacokinetic Considerations in the Treatment of Patients with Leprosy publication-title: Clin Pharmacokinet doi: 10.2165/00003088-198916060-00003 contributor: fullname: K. Venkatesan – volume: 35 start-page: 453 issue: 5 year: 2002 ident: pntd.0011901.ref016 article-title: Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia publication-title: Rev Soc Bras Med Trop doi: 10.1590/S0037-86822002000500005 contributor: fullname: IMB Goulart – volume: 11 start-page: 32 issue: 1 year: 2020 ident: pntd.0011901.ref026 article-title: Sex differences in pharmacokinetics predict adverse drug reactions in women publication-title: Biol Sex Differ doi: 10.1186/s13293-020-00308-5 contributor: fullname: I Zucker – volume: 91 start-page: 232 issue: 3 year: 2020 ident: pntd.0011901.ref038 article-title: The adverse drug effects of dapsone: a systematic review publication-title: Lepr Rev doi: 10.47276/lr.91.3.232 contributor: fullname: R Hilder – volume: 92 start-page: 194 issue: 2 year: 2012 ident: pntd.0011901.ref009 article-title: Hypersensitivity reactions to dapsone: a systematic review publication-title: Acta Derm Venereol doi: 10.2340/00015555-1268 contributor: fullname: M Lorenz – ident: pntd.0011901.ref019 – volume: 78 start-page: 216 issue: 3 year: 2007 ident: pntd.0011901.ref017 article-title: Adverse effects from multi-drug therapy in leprosy: a Brazilian study publication-title: Lepr Rev doi: 10.47276/lr.78.3.216 contributor: fullname: PD Deps – volume: 45 start-page: 1103 issue: 9 year: 2011 ident: pntd.0011901.ref015 article-title: Dapsone-Induced Methemoglobinemia: a Primer for Clinicians publication-title: Ann Pharmacother doi: 10.1345/aph.1Q139 contributor: fullname: JA Barclay – start-page: 8 year: 2014 ident: pntd.0011901.ref023 article-title: Efeitos adversos da poliquimioterapia para hanseníase: utilização de doses alternativas e avaliação pós alta publication-title: Hansen Int doi: 10.47878/hi.2014.v39.35024 contributor: fullname: RMM Kubota – volume: 395 start-page: 1509 issue: 12 year: 2022 ident: pntd.0011901.ref006 article-title: A comprehensive insight into the anti-inflammatory properties of dapsone publication-title: Naunyn Schmiedebergs Arch Pharmacol doi: 10.1007/s00210-022-02297-1 contributor: fullname: M Khalilzadeh – volume: 26 start-page: 221 issue: 2 year: 2008 ident: pntd.0011901.ref018 article-title: Noncompliance with the World Health Organization-Multidrug Therapy Among Leprosy Patients in Cebu, Philippines: Its Causes and Implications on the Leprosy Control Program. publication-title: Dermatol Clin doi: 10.1016/j.det.2007.11.007 contributor: fullname: ER Honrado – volume: 144 start-page: 525 issue: 4 year: 2016 ident: pntd.0011901.ref001 article-title: International open trial of uniform multidrug therapy regimen for leprosy patients: Findings & implications for national leprosy programmes publication-title: Indian J Med Res contributor: fullname: P Manickam – volume: 19 start-page: 79 issue: 1 year: 2001 ident: pntd.0011901.ref005 article-title: DAPSONE AND SULFAPYRIDINE publication-title: Dermatol Clin doi: 10.1016/S0733-8635(05)70231-X contributor: fullname: U Paniker – volume: 143 start-page: 722 issue: 5 year: 2023 ident: pntd.0011901.ref013 article-title: TAP2 Drives HLA-B*13:01–Linked Dapsone Hypersensitivity Syndrome Tolerance and Reactivity publication-title: J Invest Dermatol doi: 10.1016/j.jid.2022.10.009 contributor: fullname: L Sun – volume: 177 start-page: 113993 year: 2020 ident: pntd.0011901.ref031 article-title: Metabolism and interactions of antileprosy drugs publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2020.113993 contributor: fullname: J George – volume: 96 start-page: 224 issue: 2 year: 2021 ident: pntd.0011901.ref011 article-title: Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital publication-title: An Bras Dermatol doi: 10.1016/j.abd.2020.07.005 contributor: fullname: VD Tortelly – volume: 27 start-page: 429 issue: 12 year: 2017 ident: pntd.0011901.ref012 article-title: Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000306 contributor: fullname: T Tempark – volume: 30 start-page: 239 issue: 2 year: 1981 ident: pntd.0011901.ref022 article-title: A method for estimating the probability of adverse drug reactions publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1981.154 contributor: fullname: CA Naranjo – volume: 14 start-page: e0008746 issue: 10 year: 2020 ident: pntd.0011901.ref036 article-title: Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0008746 contributor: fullname: H Krismawati – ident: pntd.0011901.ref002 – volume: 12 start-page: e0189322 issue: 12 year: 2017 ident: pntd.0011901.ref032 article-title: Time to development of adverse drug reactions and associated factors among adult HIV positive patients on antiretroviral treatment in Bahir Dar City, Northwest Ethiopia publication-title: PLOS ONE doi: 10.1371/journal.pone.0189322 contributor: fullname: E Kindie – volume: 22 start-page: 7908 issue: 35 year: 2016 ident: pntd.0011901.ref035 article-title: Anemia and iron deficiency in gastrointestinal and liver conditions publication-title: World J Gastroenterol doi: 10.3748/wjg.v22.i35.7908 contributor: fullname: J Stein – volume: 20 start-page: 62 issue: 1 year: 2020 ident: pntd.0011901.ref020 article-title: World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis publication-title: BMC Infect Dis doi: 10.1186/s12879-019-4665-0 contributor: fullname: M Lazo-Porras – volume: 83 start-page: 221 issue: 3 year: 2012 ident: pntd.0011901.ref004 article-title: The chemotherapy of leprosy: an interpretive history publication-title: Lepr Rev doi: 10.47276/lr.83.3.221 contributor: fullname: RH Gelber |
| SSID | ssj0059581 |
| Score | 2.4423988 |
| Snippet | The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the successful... Background The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the... BackgroundThe occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the... BACKGROUNDThe occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the... Adverse events (AE) produced by the drugs used to treat leprosy can hinder the successful completion of the therapeutic regimen. Well-known AE produced by... Background The occurrence of adverse drug events (ADEs) during dapsone (DDS) treatment in patients with leprosy can constitute a significant barrier to the... |
| SourceID | plos doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0011901 |
| SubjectTerms | Adult Adverse and side effects Anaemia Anemia Brazil - epidemiology Care and treatment Case-Control Studies Classification Clofazimine - therapeutic use Complications and side effects Confidence intervals Dapsone Dapsone - adverse effects Diagnosis Diaminodiphenylsulfone DNA methylation Dosage and administration Drug Therapy, Combination Drug-Related Side Effects and Adverse Reactions Drugs Education Female Females Hemoglobin Hemolytic anemia Hepatotoxicity Humans Hypersensitivity Infectious diseases Leprostatic Agents - adverse effects Leprosy Leprosy - drug therapy Medical records Medicine and Health Sciences Methemoglobinemia Neutropenia Nomograms Outpatient care facilities Patients Physical Sciences Prediction models Research and Analysis Methods Rifampin - therapeutic use Risk factors Sociodemographics Statistical analysis World Health Organization |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZgDogLYm-ggJGQOIXGceLlWKBVL8ABENwsLzFUqjKjyQxS_wK_mvfsJGpQJS4cM8-ZxG_LZ_sthLxiMqjK1rxso6rKxna-tF7YklsfY9BVYz3mO599lh-_q_cnWCZnbvWFMWG5PHBm3BGLntkIIEG3rtHKKS9ZlNa1wnmlQoZGlZgWU9kHt7pN7UkBnWDGVS3HpDku2dEoozebfhfSOYQeG8JMH6VUu3_20KvNxXq4Dn7-HUV55bN0epfcGfEkPc7zuEdudP19cuvDeGL-gPy-EhVE15FamkIIf8ESGVAm3WxxJLo8mnriUMCwNFgMEemoxWbNQ0fDdv-DpkpPAz3vaQ46p7iDSy86eOPhkmIq2pZO-xL029mn_Jx0a87xunxIvp6efHl3Vo79F0oPq6IdyKsSNeMhNNxpFzqnRdCNsNy2gAJcHUUEdBgDFx6o1nrPmLOcgXxEgEv-iKx6eN0DQgEHRedc0znBG9V4DZbvfWsBnvim4rEg5SQAs8llNkw6a5OwPMmcNCgwMwqsIG9RSvNYLJKdfgDVMaPqmH-pTkFeoIxNzjidTd0cS0Q9kvOqIK_TCDR2kLG3Y84CTArLZi1GHi5GgpH6BfkA9Wiay2BgpabBmzYS75x063ryy5mMf4oxcX233g-m1nWtwf9yUZDHWRVnfnBVSwbYuCBqoaQLhi0p_fnPVF2cVQBJhVZP_geLn5LbNaDAvGd1SFa77b57Rm4OYf88GewfmsVJYg priority: 102 providerName: Directory of Open Access Journals |
| Title | Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38271456 https://www.proquest.com/docview/3069183470 https://search.proquest.com/docview/2922948836 https://pubmed.ncbi.nlm.nih.gov/PMC10846698 https://doaj.org/article/1fc1af22695b498b8c71f7ab56bc88da http://dx.doi.org/10.1371/journal.pntd.0011901 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Lb9MwGLdoD9MuiPcCYxgJiVPaOHb8OI6xqZcBEiC4RX7Eo1KXVkmLtH-Bv5rPTlI1aCeOzWenjr-Hf7a_B0LviHAy0zlNCy-zlOnKptpynVJtvXcqY9qGeOfFV_Hpp_x4GdLk8CEWJjrtW7Oc1avbWb38FX0rN7d2PviJzb9cX5AMVk2u5HyCJgAOhz16Z38LVcTSpIBMQrRVLvqAOSrIvOfPbFNvXbyDgNXwGB1RmQvCQg3rg7UppvDfG-rpZrVu70Oh_zpTHqxOV4_Qwx5W4vNu-I_Rg6p-go6u-4vzp-jPgXMQXnuscfQk_A07ZQCbeNOElsHy4VgaBwOUxU4HT5EK61Czua2wa3Y3OCZ8avGyxp3vOQ4HuXhVwYjbOxwi0ho8HE_gH4vP3f_Erl2o190z9P3q8tvFIu3LMKQWNkdbYFvGc0KdY9Qo4yqjuFOMa6oLAAMm99wDSPSOcgtUra0lxGhKiBfcwU_6HE1rGO4JwgCHvDGGVYZTJplVYACsLTSgFMsy6hOUDgwoN122jTJeuQnYpXQzWQbelT3vEvQhcGnfNuTKjg_WzU3ZS0xJvCXaA8xUhWFKGmkFDE2bghsrpdMJehN4XHaBp3uNL89FAD-C0ixB72OLoPPAY6v70AX4qJA9a9TydNQSdNWOyCdBjoZvaUvYsCkwqkyEnoNs3U9-uyeHlwbXuLpa79oyV3muwAxTnqAXnSju52MQ7ATJkZCOJmxMAZ2LScYHHXv5_11foeMcIGB3YHWKpttmV71Gk9btzuLRx1nU27-bw0pj |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdYkcZe-IYFBjMSEk9p4zjxx-MYm4pYBxJD8Bb5Ix6VurRq2kn7F_ZXc3aSqkF72mNz5zT2nc-_s-_OCH0k3IpEpTTOnUjiTJUmVoapmCrjnJVJpozPdx7_5Od_xJcTXyaHdbkwIWjf6Omwml0Nq-nfEFu5uDKjLk5s9GNyTBJYNZkUox30ECZsknReemOBc5mHy0kBm_h8q5S3KXOUk1EroeGiWtlwCgHr4R7apSLlJPO3WG-tTqGI_8ZUDxazeX0XDv0_nHJrfTp9ct-ePUWPW0SKjxr6M_SgrJ6j3Ul75v4C3W7FFeG5wwqHIMRrcLIBp-LF0nN6o4nDrToYUDC2ygeZlFj5657rEtvl-hKHWlE1nla4CVvHfg8Yz0roan2DfTLbEnc7G_j3-HvzP6FpkyV28xL9Oj25OB7H7Q0OsQG_agUST1hKqLUZ1VLbUktmZcYUVTngCJ065gBfOkuZAapSxhCiFSXEcWbhJ32FBhV87j7CgKSc1jorNaOZyIwE22FMrgDgmCyhLkJxJ7li0RTqKMJpHQcHpxnJwgu9aIUeoc9evBteX2Y7PJgvL4tWJAVxhigHCFXmOpNCC8Ph05TOmTZCWBWhQ68cRZOzujEWxRH3uIlTmkToU-Dw5gKUw6g26wE65Qtv9TgPepwwzU2PvO8VsOtLXYCvJ8EeZ9y37JTybvKHDdm_1EfVVeV8XRepTFMJFpyyCL1udHgzHt2MiJDoaXdvwPoUUOpQn7xT4jf3b3qIHo0vJmfF2dfzb2_RXgpIstn3OkCD1XJdvkM7tV2_D9P-HzYkXzE |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYkaq98A0LDGYkJJ7SJrHj2LyNbVURbEwCBG-RP-JRqUujpEXav8BfzdlJqgbtCR4bn9PYdz7_zr4PhN7EmeGRTEiYWh6FVBY6lJrJkEhtrRERldrFO8-_ZBc_-OmZS5Pzro-F8U77Wi0m5fJ6Ui5-et_K6lpPez-x6eX5SRzBrskEn1bGTvfQXVi0UdJb6q0WTkXqC5QCPnExV0nWhc2RLJ52XJpU5dr4mwjYE_fRmPAki6mrZL2zQ_lE_lt1PaqWq-Y2LPq3S-XOHjW7_z-je4DudcgUH7c0D9GdonyExufd3ftj9HvHvwivLJbYOyP-AmMb8CquakfplCf21XUwoGFspHM2KbB0ZZ-bApt6c4V9zqgGL0rcuq9jdxaMlwUMt7nBLqitxv0JB_4-_9z-j-_aRovdPEHfZmdfT-ZhV8kh1GBfrYHzEUtiYgwlSihTKMGMoEwSmQKeUIllFnCmNYRpaJVS6zhWksSxzZiBn-QpGpXwuQcIA6KySilaKEYop1qADtE6lQB0NI2IDVDYcy-v2oQdub-1y8DQaWcyd4zPO8YH6L1j8ZbWpdv2D1b1Vd6xJY-tjqUFpCpSRQVXXGfwaVKlTGnOjQzQkROQvI1d3SqN_Dhz-CkjJArQW0_h1AYIiJZd9AMMyiXgGlAeDihhuetB84ETwn4sTQ42nwC9TDPXsxfM25tfb5vdS513XVmsNk2eiCQRoMkJC9CzVo6389GvigDxgYQPJmzYAoLt85T3gvz837seofHl6Sz_9OHi4wu0nwCgbI-_DtFoXW-Kl2ivMZtXfuX_AQM8YbE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+multivariate+predictive+model+for+dapsone+adverse+drug+events+in+people+with+leprosy+under+standard+WHO+multidrug+therapy&rft.jtitle=PLoS+neglected+tropical+diseases&rft.au=Ana+Carolina+Galv%C3%A3o+dos+Santos+de+Araujo&rft.au=Mariana+de+Andrea+Vilas-Boas+Hacker&rft.au=Roberta+Olmo+Pinheiro&rft.au=Illarramendi%2C+Ximena&rft.date=2024-01-01&rft.pub=Public+Library+of+Science&rft.issn=1935-2727&rft.eissn=1935-2735&rft.volume=18&rft.issue=1&rft.spage=e0011901&rft_id=info:doi/10.1371%2Fjournal.pntd.0011901&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1935-2735&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1935-2735&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1935-2735&client=summon |